Pharmaceutical

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") was honoured to join the Globe and Mail's recent Health Care Innovation event, featuring leaders from various corners of the sector, including Company CEO, Hector Bremner.

"With about 40% of patients in Canada saying it's difficult to access a diagnostics test and nine million expressing difficulty in getting access to care, it's clear that the time is now to support more services in community pharmacy," says Avricore Health Inc. CEO, Hector Bremner. "HealthTab is already playing a significant role in supporting better services in pharmacy and we're going to continue to advocate for patients, and providers, so better outcomes for all are achieved."

The Globe and Mail's event featured health sector leaders, academics, governmental agency representatives, physicians, and patient advocates. For a full list of participants and to watch the webcast in its entirety, it can be viewed at the Globe and Mail's site at the following link: https://www.theglobeandmail.com/events/article-new-approaches-to-health-care-delivery/ .

Also, for reference to the above-mentioned observations on Canadian patient experience and sentiment around the current healthcare challenges, please view the recent Angus Reid Institutes series of polling data here: https://angusreid.org/canada-health-care-issues/ .

HealthTab™ Market Fast Facts

  • Point of Care Testing Market to reach $93.21 Billion USD in 2030 ( Source ).
  • Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed ( Source ).
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ( Source ).
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed ( Source ).
  • There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

About HealthTab™

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Contact :

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCR:CA
avricore

Avricore Health


Keep reading...Show less
Avricore Health Announces CEO Update Call on Sept. 22, 2022

Avricore Health Announces CEO Update Call on Sept. 22, 2022

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to offer a live discussion on the Company's current activities and forward outlook as it executes a significant national scale-up of its pharmacy-based point-of-care platform, HealthTab.

"We're currently deploying a significant expansion of HealthTab systems and we're on track to achieve our revenue goals, as well as getting to cash flow positivity," said Avricore Health CEO, Hector Bremner. "It's an exciting time for the Company and we're looking forward to discussing the recent successes and future objectives."

Call Details:

September 22, 2022 @ 11:00am PT / 2:00pm ET via Zoom
Register here to receive login details: Investor@avricorehealth.com

Agenda:

The 60-minute call agenda will be as follows:
10min: Opening Remarks / Team Introductions
30Min: Overview Presentation and Update
20Min: Q&A

We're looking forward to seeing you there, please review our most recent investor presentation here: www.avricore.com

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Reports Second-Quarter 2022 Results

Avricore Health Reports Second-Quarter 2022 Results

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to provide this corporate update on the Company's Q2 results.

"We have now begun a new era for Healthtab™ and the Company as we expand Shoppers Drug Mart significantly over the coming weeks," said Hector Bremner, CEO of Avricore Health Inc. "We are now realizing our revenue targets and are on track to realize long-term profitability as we continue to successfully execute our plan."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Grants Options

Avricore Grants Options

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to announce that the Company's board of directors has approved the granting of stock options (the "Options") exercisable for a total of 2,725,000 common shares to its directors, officers, and consultants at an exercise price of CAD$0.15 per common share.

All Options were granted pursuant to the Company's stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Executing Growth Strategy - Summer 2022 Corporate Update

Avricore Health Executing Growth Strategy - Summer 2022 Corporate Update

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to provide this corporate update on the Company's activities and progress in the first five months of 2022, as well as an outlook on the Company's objectives and expectations for the balance of the year.

"At the beginning of the year, we laid out a plan to expand our point-of-care testing platform in pharmacies across Canada and beyond and begin to generate more substantial revenues," said Hector Bremner, CEO of Avricore Health Inc. "Our progress towards those objectives has been significant, and we are very confident in our current client negotiations and planning."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to be joined by Shoppers Drug Mart Pharmacist and Associate Owner, Mohamad Adel Elsabakhawi and Abbott Rapid Diagnostics' General Manager Daniel St. Pierre and National Sales Manager, Soul Khan.

"The Company enjoyed an incredible year in 2021, and throughout the Holidays and the beginning of the New Year, we have continued to finalize key agreements which will lead to substantial growth this year." said Avricore Health CEO, Hector Bremner. "Our partners are as excited as we are and we look forward to deepening our collaboration."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
PowerTap Hydrogen Announces That Its 49% owned subsidiary, Progressus Clean Technologies Has Executed a Letter of Intent with Alkaline Fuel Cell Power Corp. for Clean Hydrogen Joint Venture Pilot

PowerTap Hydrogen Announces That Its 49% owned subsidiary, Progressus Clean Technologies Has Executed a Letter of Intent with Alkaline Fuel Cell Power Corp. for Clean Hydrogen Joint Venture Pilot

  • Pilot project to provide in-field proof of concept and operational data
  • Advancing a potential solution for global utility companies to blend hydrogen and natural gas
  • JV structured to support potential future growth and additional partnerships

PowerTap Hydrogen Capital Corp. (NEO: MOVE) (FWB: 2K6) (OTC: MOTNF) ("PowerTap" or the "Company" or "MOVE") is pleased to provide an update and details on Progressus Clean Technologies Inc. ("Progressus") entering into a letter of intent with Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP") to complete a joint venture ("JV") pilot project that aims to provide a solution for natural gas utilities to directly power both residential and commercial businesses. AFCP is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. The JV is intended to provide proof of concept for each company's technologies and assess the ability to combine various Progressus technologies with AFCP fuel cells to serve residential and small building customers across North America. PowerTap owns 49% of Progressus.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
dynaCERT's Program with Alectra Utilities Corporation Achieves Coveted Sustainability Award

dynaCERT's Program with Alectra Utilities Corporation Achieves Coveted Sustainability Award

dynaCERT Inc. (TSX: DYA) (OTCQX: DYFSF) (FRA: DMJ) (" dynaCERT " or the "Company") is pleased to announce that yesterday the Windfall Ecology Centre, a Canadian non-profit social enterprise, has recognized Alectra Utilities Corporation ("Alectra") for its use of dynaCERT' s HydraGEN™ Technology to reduce the emissions and fuel costs of fleet vehicles.

Alectra is the largest municipally owned electric utility in Canada by customer base. See: https://alectrautilities.com/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th

BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

"Our mission is to find solutions for advanced breast cancer patients who do not respond to current treatments. We are thrilled for the opportunity to share our clinical findings with clinicians who treat similar, difficult-to-treat patients," stated Dr. Bill Williams, BriaCell's President & CEO.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
GMG Acquires THERMAL-XR Manufacturing Intellectual Property and Brand Rights and Grants RSUs to Directors and Officers

GMG Acquires THERMAL-XR Manufacturing Intellectual Property and Brand Rights and Grants RSUs to Directors and Officers

Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG") is pleased to announce that, further to its news release dated August 15, 2022, GMG has completed the acquisition of the manufacturing intellectual property and brand rights of OzKem Pty Ltd.'s ("OzKem") THERMAL-XR® coating products. OzKem developed the THERMAL-XR® coating system products using GMG graphene together with OzKem's base HVAC (Heating Venting and Air Conditioning) coating. GMG is an international distributor of THERMAL-XR® products with a number of global commercial demonstrations underway or initial sales completed. GMG now owns the THERMAL-XR® brand, will buy the base coatings product from OzKem, and will manufacture the THERMAL-XR® products containing GMG graphene.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Nano One and Euro Manganese Validate Manganese Metal in M2CAM Process

Nano One and Euro Manganese Validate Manganese Metal in M2CAM Process

nano one ® Materials Corp. (TSX: NANO; OTC: NNOMF; Frankfurt: LBMB) ("nano one")

VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) ("Euro Manganese")

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Alkaline Fuel Cell Power Corp. Announces Filing and Mailing of Information Circular for Special Meeting of Shareholders

Alkaline Fuel Cell Power Corp. Announces Filing and Mailing of Information Circular for Special Meeting of Shareholders

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" AFCP " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce the SEDAR filing and physical mailing of a management information circular dated September 26, 2022 (the " Circular ") and related meeting and proxy materials in connection with its upcoming special meeting of shareholders to be held on October 17, 2022 (the " Special Meeting ").

At the Special Meeting, AFCP will seek shareholder approval to amend the exercise price of certain outstanding common share purchase warrants (the " Warrants ") of the Company from between $0.75 and $0.33 (which is significantly above current trading prices for the common shares of the Company (the " Common Shares ") to $0.20 (the " Warrant Amendments "). In accordance with the polices of the NEO Exchange (the " NEO "), those holders of Warrants who are advantaged by the proposed Warrant Amendments will be excluded from voting on the Warrant Amendments. The particulars of the Warrant Amendments are further disclosed in the Circular.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×